#Switzerland #Drug Pricing #EVERSANA #Basel #Lyfegen

Transforming Drug Pricing and Access with AI

In a groundbreaking announcement, Lyfegen, a leader in drug market access and pricing solutions, has teamed up with EVERSANA®, a premier global provider of commercial services for the life sciences industry. This innovative collaboration is set to transform how the healthcare sector addresses drug pricing and access challenges using artificial intelligence.

Understanding the Challenges of Drug Pricing

The landscape of drug pricing and access is becoming increasingly complicated. Healthcare providers often grapple with inefficiencies and delays that can hinder patient access to critical medications. The collaboration between Lyfegen and EVERSANA aims to bridge these gaps by leveraging their respective strengths: EVERSANA's NAVLIN platform and Lyfegen's Public Drug Agreement Library.

Harnessing AI for Smarter Decisions

Combining Resources for a 360-Degree Perspective

By integrating data and functionalities from the NAVLIN platform—recognized as the industry's most comprehensive pricing and access solution—alongside Lyfegen's comprehensive repository of over 7,000 public pricing agreements, this partnership offers an unprecedented view of drug pricing trends. This AI-driven synergy not only equips market access professionals with critical insights but also fosters smarter decision-making through enhanced predictive analytics.

Key Features of the Collaboration

• - Efficiently Link Agreements: The partnership connects public drug agreements with real-time pricing and access data, all within a single collaborative environment.
• - Market-Specific Solutions: Users can discover pricing agreements tailored to specific market conditions and regulatory needs.
• - Streamlined Decision-Making: The combination of real-time data and AI analytics allows for faster and more accurate decision-making in a rapidly changing market landscape.

Promoting Fair and Timely Access to Therapies

With many patients unable to access the medications they need due to prohibitive costs, this partnership represents a significant leap towards ensuring equitable healthcare access. Jim Lang, CEO of EVERSANA, states, "Together with Lyfegen we can harness the power of AI to address one of the biggest challenges in healthcare—helping patients get timely access to life-saving medicines."

The integrated strategies aim to minimize waste and enhance efficiency throughout the drug delivery continuum, ultimately benefiting millions of patients globally.

The Future Landscape of Drug Access

The partnership places Lyfegen and EVERSANA at the forefront of a healthcare sector that is increasingly turning to artificial intelligence as a means to innovate and improve operational efficiency. Girisha Fernando, CEO of Lyfegen, emphasizes the importance of their collaboration, stating, "Through our partnership, we are taking significant steps toward a more sustainable and equitable healthcare environment. Not only are we addressing current challenges, but we are also paving the way for a more intelligent drug access and pricing ecosystem."

Conclusion

As the healthcare industry adapts to new technologies and methodologies, the partnership between Lyfegen and EVERSANA signals a promising direction for drug pricing and access management. By utilizing AI to manage complexities and enhance decision-making efficiency, this alliance is not just about addressing today's issues; it's about building a smarter, fairer future for healthcare.

Learn more about this collaboration and how it will impact the global healthcare environment by visiting Lyfegen and EVERSANA.